Results 201 to 210 of about 10,516 (266)

Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up. [PDF]

Proc (Bayl Univ Med Cent)
Hlavinka WJ, Mbilinyi RH, Sontam TR, Mantilla EC, Mella DB.   +4 more
europepmc   +1 more source

Prognostic value of PANOMEN-3 classification for hypopituitarism in surgically and nonoperatively managed pituitary adenomas. [PDF]

Endocr Connect
Nakhleh A, Ayada G, Assalia Naffa M, Sviri G, Zolotov S.   +4 more
europepmc   +1 more source

Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. [PDF]

Case Rep Med
Guimarães GNF.
europepmc   +1 more source

Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum-Insights From a 7-Year Cohort Study. [PDF]

Breast J
AkbariRad M, Sheybani F, Firoozi A, Sajjadi S, Emadzadeh M, Kazerani M, Ataei Azimi S, Mottaghi M.   +7 more
europepmc   +1 more source

Surgery for prolactinomas.

, 2006
A A Razzaq, Rashid Jooma, Shahid Ahmed
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prolactinomas

Endocrinology and Metabolism Clinics of North America, 2015
Identifying the correct cause of hyperprolactinemia is crucial for treatment. Prolactinoma is the most common pathologic cause of hyperprolactinemia. Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Neurosurgery, mainly by the transsphenoidal route,
Andrea, Glezer, Marcello D, Bronstein
openaire   +2 more sources